Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study

Trial Profile

Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genmab; Janssen-Cilag
  • Most Recent Events

    • 01 Aug 2017 Results of pooled analysis assessing comparison of Daratumumab monotherapy in GEN501 and SIRIUS study versus real world two independent US databases ;IMS-LifeLink and OPTUM, presented in American Journal of Hematology.
    • 25 Jun 2017 Data from this and other trial comparing Daratumumab with Standard of Care in prolonging survival; results presented at the 22nd Congress of the European Haematology Association
    • 17 Jun 2017 This trial has been completed in Denmark (end date: 3 Apr 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top